Long-acting injectable olanzapine can give rise to a condition consistent with central anticholinergic syndrome.
Tor
T
Skomedal
Sigrid
S
Hanem
Terje
T
Dybvik
Stein Opjordsmoen
SO
Ilner
D064807:Anticholinergic Syndrome / Q000188:drug therapy / Q000209:etiology; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D003693:Delirium / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000627:therapeutic use; D007273:Injections, Intramuscular; D000077152:Olanzapine; D010830:Physostigmine / Q000008:administration & dosage / Q000627:therapeutic use; D013577:Syndrome
D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D003692:Delayed-Action Preparations; D006993:Hypnotics and Sedatives; D001569:Benzodiazepines; D010830:Physostigmine; D000077152:Olanzapine